

MEDICAL UPDATE LETTER FOR DONOR #12445 (MAYNARD) - 2026-08-04

Donor 12445 (Maynard) was recently reported to be a carrier of a genetic condition, called alpha-1 antitrypsin deficiency. This condition was not included in his prior carrier screening. This letter is intended for all recipients and facilities who have utilized vials from Donor 12445 (Maynard) to make them aware and provide follow-up suggestions.

To Whom it May Concern,

We are writing to provide a medical update regarding Donor #12445 (Maynard).

Donor 12445 (Maynard) was found to be a carrier of a clinically significant variant in the SERPINA1 gene. He is heterozygous (one copy) for a pathogenic variant in SERPINA1, specifically the PI*Z allele.

The SERPINA1 gene is associated with autosomal recessive alpha-1 antitrypsin deficiency (AATD). AATD is characterized by lung and liver disease. However, many people with this condition remain asymptomatic. Lung symptoms may begin in adulthood and can progress to severe breathing issues or emphysema. Liver disease can develop at any age, with most cases diagnosed in adulthood. Rarely, liver disease can be present in infancy or childhood.

Affected individuals inherit two variants in the SERPINA1 gene, one from the egg source and one from the sperm source. With this variable condition, disease severity may be assessed based on the combination of inherited SERPINA1 variants.

Carriers of SERPINA1, like Donor 12445 (Maynard), are not expected to exhibit symptoms. However, some carriers of SERPINA1 who smoke or have other environmental risk factors may have an increased risk for lung and liver disease.

Interpretation:

All children/embryos resulting from Donor 12445 (Maynard) have a 50% chance to have inherited the SERPINA1 variant.

Next Steps for Families who have Utilized the Donor:

Please share this letter and the attached report with your doctors. The egg source of any embryos/children resulting from Donor 12445 (Maynard) may consider carrier screening for mutations in the SERPINA1 gene.

- If the egg source of any child/embryo is also a carrier of a mutation in the SERPINA1 gene, there is a 1 in 4 (25%) chance that each resulting child/embryo will inherit both mutations and be affected with AATD.
- If the egg source of any child/embryo screens negative for a variant in the SERPINA1 gene, the risk to have a child affected with AATD is significantly reduced.


Do not hesitate to reach out if questions arise or if clarification would be helpful. You are welcome to schedule a phone consultation with one of Seattle Sperm Bank's certified genetic counselors if you would like to discuss this information over the phone.

In partnership,

August 4, 2026



Olivia Hess, MS, CGC
Certified Genetic Counselor
Seattle Sperm Bank
(206) 588-1484
Genetics@SeattleSpermBank.com



Emily Nazar, MS, CGC
Certified Genetic Counselor
Seattle Sperm Bank
(206) 588-1484
Genetics@SeattleSpermBank.com



Brynn Persky, MS, CGC
Certified Genetic Counselor
Seattle Sperm Bank
(206) 588-1484
Genetics@SeattleSpermBank.com



James Kuan, MD
Medical Director
Seattle Sperm Bank
(206) 588-1484
James@seattlespermbank.com